{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:10:40Z","timestamp":1787015440181,"version":"build-2736575974"},"reference-count":18,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with prurigo nodularis (PN) have multiple itchy nodules, impaired quality of life and sleep deprivation. Prurigo nodularis patients have a high burden of disease, primarily due to the intensity of the itch. It is reasonable to expect that rapid relief of itch \u2013 and associated improvement of sleep \u2013 are highly valued clinical outcomes for patients. Nemolizumab is an IL\u201031A\u2010receptor inhibitor that modulates the neuroimmune response with reported positive efficacy and safety data in a phase 2 study of PN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the onset of action of nemolizumab on itch and sleep disturbances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Post hoc<\/jats:italic>\n                      analysis of a phase 2 trial of nemolizumab 0.5\u2009mg\/kg SC vs. placebo in patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200970) with moderate\u2010to\u2010severe PN (\u226520 nodules) and severe pruritus (NRS\u2009\u2265\u20097). Time to significant reduction was assessed for peak pruritus (PP) and sleep disturbance (SD) using numerical rating scales (NRS), also assessed was scratching time during sleep.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nemolizumab significantly reduced itch vs. placebo within 48\u2009h (PP NRS \u221219.5% vs. \u22125.8%, respectively,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.014). Significant difference between nemolizumab and placebo in reducing itch by \u22654 on PP NRS was achieved at Day 3 (23.5% vs. 0%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). A significant difference in SD NRS was reported by Day 4 (\u221224.0% vs. \u22124.3% placebo,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.012). In addition, there was a separation between groups in SD responders (decrease of \u22654 points) in favour of nemolizumab by Day 2 (8.8% vs. 0%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.037). Sleep continued improving through Week 4, when there was a \u221256.0% reduction in SD NRS vs. \u221222.9% placebo (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Actigraphy data showed improvement in scratch\/sleep duration for nemolizumab vs. placebo, respectively, by Week 1 (\u221232.15 vs. +28.15\u2009min\/h,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nemolizumab has a rapid and robust onset of action in PN with itch reduction and improvement of sleep within 48\u2009h.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.18377","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T05:25:06Z","timestamp":1656480306000},"page":"1820-1825","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances"],"prefix":"10.1111","volume":"36","author":[{"given":"S.","family":"St\u00e4nder","sequence":"first","affiliation":[{"name":"Department of Dermatology and Center for Chronic Pruritus University Hospital M\u00fcnster  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Yosipovitch","sequence":"additional","affiliation":[{"name":"Itch Center, Dr Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Hospital  Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010P.","family":"Lacour","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Nice  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"Legat","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Medical University of Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-1754","authenticated-orcid":false,"given":"A.","family":"Reich","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Rzeszow  Rzeszow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chaouche","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Galderma Laboratories LP  Fort Worth Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-2478","authenticated-orcid":false,"given":"C.","family":"Piketty","sequence":"additional","affiliation":[{"name":"Galderma R&amp;D  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.05.051"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15145"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.022"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S188070"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1852080"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16929"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3571"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649332"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6030088"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1707469"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/itx.0000000000000042"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908316"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20783"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.013"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.049"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1853024"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.052"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.639097"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18377","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T11:45:49Z","timestamp":1692445549000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/jdv.18377"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18377","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"2021-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}